Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-154 |
Sentence |
denotes |
Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. |
T1 |
0-154 |
Sentence |
denotes |
Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. |
T2 |
155-166 |
Sentence |
denotes |
UNLABELLED: |
T2 |
155-166 |
Sentence |
denotes |
UNLABELLED: |
T3 |
167-340 |
Sentence |
denotes |
The receptor binding domain (RBD) of the spike (S) glycoprotein of severe acute respiratory syndrome coronavirus (SARS-CoV) is a major target of protective immunity in vivo. |
T3 |
167-340 |
Sentence |
denotes |
The receptor binding domain (RBD) of the spike (S) glycoprotein of severe acute respiratory syndrome coronavirus (SARS-CoV) is a major target of protective immunity in vivo. |
T4 |
341-572 |
Sentence |
denotes |
Although a large number of neutralizing antibodies (nAbs) have been developed, it remains unclear if a single RBD-targeting nAb or two in combination can prevent neutralization escape and, if not, attenuate viral virulence in vivo. |
T4 |
341-572 |
Sentence |
denotes |
Although a large number of neutralizing antibodies (nAbs) have been developed, it remains unclear if a single RBD-targeting nAb or two in combination can prevent neutralization escape and, if not, attenuate viral virulence in vivo. |
T5 |
573-875 |
Sentence |
denotes |
In this study, we used a large panel of human nAbs against an epitope that overlaps the interface between the RBD and its receptor, angiotensin-converting enzyme 2 (ACE2), to assess their cross-neutralization activities against a panel of human and zoonotic SARS-CoVs and neutralization escape mutants. |
T5 |
573-875 |
Sentence |
denotes |
In this study, we used a large panel of human nAbs against an epitope that overlaps the interface between the RBD and its receptor, angiotensin-converting enzyme 2 (ACE2), to assess their cross-neutralization activities against a panel of human and zoonotic SARS-CoVs and neutralization escape mutants. |
T6 |
876-1033 |
Sentence |
denotes |
We also investigated the neutralization escape profiles of these nAbs and evaluated their effects on receptor binding and virus fitness in vitro and in mice. |
T6 |
876-1033 |
Sentence |
denotes |
We also investigated the neutralization escape profiles of these nAbs and evaluated their effects on receptor binding and virus fitness in vitro and in mice. |
T7 |
1034-1268 |
Sentence |
denotes |
We found that some nAbs had great potency and breadth in neutralizing multiple viral strains, including neutralization escape viruses derived from other nAbs; however, no single nAb or combination of two blocked neutralization escape. |
T7 |
1034-1268 |
Sentence |
denotes |
We found that some nAbs had great potency and breadth in neutralizing multiple viral strains, including neutralization escape viruses derived from other nAbs; however, no single nAb or combination of two blocked neutralization escape. |
T8 |
1269-1507 |
Sentence |
denotes |
Interestingly, in mice the neutralization escape mutant viruses showed either attenuation (Urbani background) or increased virulence (GD03 background) consistent with the different binding affinities between their RBDs and the mouse ACE2. |
T8 |
1269-1507 |
Sentence |
denotes |
Interestingly, in mice the neutralization escape mutant viruses showed either attenuation (Urbani background) or increased virulence (GD03 background) consistent with the different binding affinities between their RBDs and the mouse ACE2. |
T9 |
1508-1717 |
Sentence |
denotes |
We conclude that using either single nAbs or dual nAb combinations to target a SARS-CoV RBD epitope that shows plasticity may have limitations for preventing neutralization escape during in vivo immunotherapy. |
T9 |
1508-1717 |
Sentence |
denotes |
We conclude that using either single nAbs or dual nAb combinations to target a SARS-CoV RBD epitope that shows plasticity may have limitations for preventing neutralization escape during in vivo immunotherapy. |
T10 |
1718-1949 |
Sentence |
denotes |
However, RBD-directed nAbs may be useful for providing broad neutralization and prevention of escape variants when combined with other nAbs that target a second conserved epitope with less plasticity and more structural constraint. |
T10 |
1718-1949 |
Sentence |
denotes |
However, RBD-directed nAbs may be useful for providing broad neutralization and prevention of escape variants when combined with other nAbs that target a second conserved epitope with less plasticity and more structural constraint. |
T11 |
1950-1961 |
Sentence |
denotes |
IMPORTANCE: |
T11 |
1950-1961 |
Sentence |
denotes |
IMPORTANCE: |
T12 |
1962-2183 |
Sentence |
denotes |
The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 has resulted in severe human respiratory disease with high death rates. |
T12 |
1962-2183 |
Sentence |
denotes |
The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 has resulted in severe human respiratory disease with high death rates. |
T13 |
2184-2307 |
Sentence |
denotes |
Their zoonotic origins highlight the likelihood of reemergence or further evolution into novel human coronavirus pathogens. |
T13 |
2184-2307 |
Sentence |
denotes |
Their zoonotic origins highlight the likelihood of reemergence or further evolution into novel human coronavirus pathogens. |
T14 |
2308-2606 |
Sentence |
denotes |
Broadly neutralizing antibodies (nAbs) that prevent infection of related viruses represent an important immunostrategy for combating coronavirus infections; however, for this strategy to succeed, it is essential to uncover nAb-mediated escape pathways and to pioneer strategies that prevent escape. |
T14 |
2308-2606 |
Sentence |
denotes |
Broadly neutralizing antibodies (nAbs) that prevent infection of related viruses represent an important immunostrategy for combating coronavirus infections; however, for this strategy to succeed, it is essential to uncover nAb-mediated escape pathways and to pioneer strategies that prevent escape. |
T15 |
2607-2756 |
Sentence |
denotes |
Here, we used SARS-CoV as a research model and examined the escape pathways of broad nAbs that target the receptor binding domain (RBD) of the virus. |
T15 |
2607-2756 |
Sentence |
denotes |
Here, we used SARS-CoV as a research model and examined the escape pathways of broad nAbs that target the receptor binding domain (RBD) of the virus. |
T16 |
2757-2834 |
Sentence |
denotes |
We found that neither single nAbs nor two nAbs in combination blocked escape. |
T16 |
2757-2834 |
Sentence |
denotes |
We found that neither single nAbs nor two nAbs in combination blocked escape. |
T17 |
2835-3045 |
Sentence |
denotes |
Our results suggest that targeting conserved regions with less plasticity and more structural constraint rather than the SARS-CoV RBD-like region(s) should have broader utility for antibody-based immunotherapy. |
T17 |
2835-3045 |
Sentence |
denotes |
Our results suggest that targeting conserved regions with less plasticity and more structural constraint rather than the SARS-CoV RBD-like region(s) should have broader utility for antibody-based immunotherapy. |